Pancreatic Cancer MSK 16-1066

Sponsor: Memorial Sloan Kettering Cancer Center

Number: MSK 16-1066

Pilot Study of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

In this study, patients with advanced pancreatic cancer will receive gemcitabine, nab-paclitaxel, and PEGPH20 along with the drug rivaroxaban. This medication is used to reduce the risk of blood clots. It is a pill that is taken orally (by mouth); gemcitabine, nab-paclitaxel, and PEGPH20 are given intravenously (by vein). Researchers hope that the three anticancer drugs will shrink pancreatic tumors and that the addition of rivaroxaban (evaluated here at two different doses) will lower the chance of developing a blood clot during treatment.

A prior study of gemcitabine, nab-paclitaxel, and PEGPH20 showed that patients receiving this treatment had an increased risk of blood clots.

Who’s eligible:

  • Patients must have inoperable (stage III) or metastatic (stage IV) adenocarcinoma of the pancreas.
  • No prior treatment is permitted for stage III disease. Patients with metastatic cancer may have received previous treatment with gemcitabine or 5-FU for non-metastatic cancer, with at least 6 months passing between the completion of therapy and entry into the study.

Available at: The Hospital of Central Connecticut, MidState Medical Center, Backus Hospital- Eastern Connecticut Hematology and Oncology, and Hartford Hospital.

Cancer Clinical Research Office